# To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Study · id `cardio:ct-nct06647550` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06647550](<https://clinicaltrials.gov/study/NCT06647550>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06647550

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT06647550. Randomized; double masking; primary purpose treatment. Start 2024-12-12 (actual); primary completion 2025-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT06647550, source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)
- Started: 2024-12-12 (actual) (ClinicalTrials.gov record NCT06647550, source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)
- Primary completion: 2025-03-31 (anticipated) (ClinicalTrials.gov record NCT06647550, source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06647550, source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06647550, source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06647550-2024-12-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Acronym: HDNO-1605
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): HD-6277 100mg
- Intervention (Drug): HD-6277 50mg
- Intervention (Drug): HD-6277 25mg
- Intervention (Drug): Placebo
- Lead sponsor: Hyundai Pharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hyundai Pharm (`cardio:org-hyundai-pharm`)

## Provenance

Content hash: 95c8c0df2828875f7ded32c24b5fe0df2fc871c4333b273cc48b483e3dc9840c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
